You forget to read the history of what happened. TEVA was profitable, leading No 1 generic drug company two years before paying 3.5% dividends. Since they took over a company , on cash, heavily debted to 36B, and the taken over company was not profitable. CEO was thrown out for that take over, new CEO came.
The stock dived from $70 (when profitable) to $10.5, and new CEO initiated restructuring plan (11/2017) after reducing the debt from 36B. Warren buffet started buying from $14.50 onwards. So far, he bought three times whenever it dipped. TEVA is still profitable without the new takeover. The CEO is aggressively selling unprofitable units to pay off the debt. They restructured entire USA operations to reduce over head and he is producing results beyond/beating analysts expectation last 3 quarters.
The EpiPen is the major market in USA. So far MYL is the one and only approved provider of EpiPen which has huge market. For the first time, after 2016 election EpiPen issue, FDA approved Teva as generic drug provider of Epipen. This means a major win and stock going up. MYL (Competitor) sells 8 Million Epipen every year at $600 around price, which is earning appx $400 M profit. Now, TEVA will have some share of this profit.
The restructuring/recovery will reduce considerable debt in 2 years (as per CEO) and he is well known to bring back such companies.
Warren buffet is just an indicator what to buy,…that is all. After he bought TEVA, the next 3 quarters TEVA beat analysts consensus every time.
BTW: I am heavy in TEVA, bought more today too based on epipen approval. TEVA alone is 40% up for me YTD.